Answers are grounded in this paper and cite their sources.
The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.
No takes yet. Share an insight, caveat, or question.
Davidson et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: